rs7927894 — EMSY

EMSY — The Epigenetic Gatekeeper of the Skin Barrier

On chromosome 11q13.5, a single regulatory variant, rs7927894, sits near one of the most consequential genes in allergic disease genetics. The T allele at this position raises expression of EMSY¹¹ EMSY
EMSY (C11orf30) is a chromatin-associated protein that epigenetically silences gene expression by recruiting histone-modifying complexes; it was first described as a BRCA2-interacting protein amplified in breast and ovarian cancer — and higher EMSY activity turns down the genes that build and maintain the skin's waterproof barrier. This locus is the broadest-acting allergic disease susceptibility signal in the human genome, influencing risk for eczema, asthma, hay fever, and the progressive atopic march from early childhood eczema to later-onset respiratory and food allergies.

The Mechanism

EMSY is a chromatin regulatory protein that acts as a transcriptional repressor. It binds chromatin-modifying complexes and silences nearby target genes by altering histone modifications at their promoters. In skin, EMSY's key targets include genes encoding filaggrin²² filaggrin
Filaggrin (FLG) is a structural protein that aggregates keratin filaments in the outermost skin layer and is broken down into natural moisturising factors; loss-of-function FLG mutations are the strongest known single-gene risk factor for eczema, filaggrin-2, and enzymes that synthesise long-chain ceramides — the lipid molecules that seal the space between skin cells and prevent water loss and allergen entry.

Mechanistic studies³³ Mechanistic studies
Elias MS, Brown SJ, J Allergy Clin Immunol 2019 — siRNA knockdown and overexpression experiments in organotypic skin models directly demonstrated that reducing EMSY activity enhances barrier development: filaggrin, filaggrin-2, and long-chain ceramide levels all increase when EMSY is silenced. Conversely, overexpression of EMSY reduces these same barrier markers. In skin biopsy samples from atopic dermatitis patients, EMSY nuclear staining is increased compared with non-atopic controls, consistent with a gain-of-repression model: the rs7927894 T allele drives higher EMSY expression, which suppresses barrier gene transcription, which compromises the skin's physical defences and permits allergen sensitisation. A second nearby gene, LRRC32 (encoding GARP), lies within the same topologically associating domain and has independently been linked to atopic dermatitis through its role in regulatory T-cell activation and TGF-β signalling, suggesting this locus has at least two distinct mechanisms converging on allergic susceptibility.

The Evidence

rs7927894 was identified in a 2009 genome-wide scan⁴⁴ 2009 genome-wide scan
Esparza-Gordillo et al., Nat Genet — 939 cases and 975 controls in discovery, 2,637 cases and 3,957 controls in replication across European cohorts as the primary GWAS hit for atopic dermatitis at 11q13.5 (combined p=7.6×10⁻¹⁰). Homozygous T allele carriers (TT) had an odds ratio of 1.47 for atopic dermatitis compared with CC individuals; heterozygous CT carriers had intermediate risk consistent with additive inheritance.

The locus has been replicated across multiple independent cohorts. A large meta-GWAS⁵⁵ large meta-GWAS
Paternoster et al., Nat Genet 2011 — discovery cohort 5,606 affected individuals and 20,565 controls, replication 5,419 and 19,833 confirmed the 11q13.5 locus signal. In the 9,300-participant ALSPAC birth cohort⁶⁶ 9,300-participant ALSPAC birth cohort
Marenholz et al., Hum Mol Genet 2011 — prospective UK birth cohort with longitudinal phenotyping of atopic conditions, the T allele was associated not only with eczema but also with atopic asthma and hay fever, with the strongest effects seen in combined phenotypes: eczema plus asthma (OR=1.50) and eczema plus hay fever (OR=1.37). The population attributable risk fraction was estimated at 9.3% for eczema and approximately 25% for eczema-associated asthma or hay fever — a substantial contribution from a single common variant.

A 2015 meta-analysis⁷⁷ 2015 meta-analysis
Marenholz et al., Nat Commun — 12 populations, 2,428 combined eczema+asthma cases and 17,034 controls confirmed C11orf30/LRRC32 as one of seven loci contributing to the atopic march. The Polish ECAP cohort study⁸⁸ Polish ECAP cohort study
Ponińska et al., PLoS One 2017 found that the T allele was associated with atopic dermatitis (OR=1.39) and persistent allergic rhinitis (OR=1.24) in a haplotype-dependent manner, with the effect restricted to haplotypes also encoding G at rs7125552.

The interaction with filaggrin mutations⁹⁹ filaggrin mutations
O'Regan et al., J Allergy Clin Immunol 2010 — 511 Irish pediatric eczema cases and 1,000 controls; FLG mutations carried OR=5.81 is particularly clinically important. The rs7927894 T allele effect is independent of and additive with FLG mutations. In a paediatric Polish cohort¹⁰¹⁰ paediatric Polish cohort
Dębińska et al., Postepy Dermatol Alergol 2020 — 188 children under 2 years, carrying both the T allele and a filaggrin loss-of-function mutation raised atopic dermatitis odds to OR=16.41 — far exceeding the effect of either variant alone.

Practical Actions

The EMSY T allele acts upstream of filaggrin and ceramide production. This means carriers have a genetically reduced capacity to maintain the skin barrier — even without carrying FLG loss-of-function mutations. The practical priority is barrier support and early recognition of atopic progression.

Ceramide-containing emollient therapy is the most mechanistically specific intervention for EMSY T allele carriers: since the risk operates partly by reducing ceramide synthesis, topical ceramide replacement directly addresses the underlying deficit. For established atopic dermatitis, regular application of ceramide-dominant emollients helps restore barrier integrity and reduce itch and inflammation severity. This is distinct from the question of emollient use in newborns for primary prevention — randomised trial evidence (BEEP trial, PMID 32087126) does not support daily emollient in infancy as a primary prevention strategy for eczema in high-risk infants and found no benefit alongside some increase in skin infection risk.

Early allergen introduction during weaning (4–6 months) significantly reduces food allergy risk in infants with eczema (peanut: LEAP trial, PMID 25705822 — 86% relative risk reduction in high-risk infants). Since rs7927894 T allele carriers are at elevated risk for the full atopic march — including food allergy as part of allergen sensitisation through barrier breach — early diversified allergen introduction is a priority management strategy.

Interactions

The most clinically important interaction is with filaggrin (FLG) loss-of-function variants (rs61816766, rs12123821 and others). Both loci converge on the same biological pathway — epithelial barrier maintenance — but through different mechanisms: FLG directly encodes the barrier structural protein, while EMSY regulates its transcription. When both vulnerabilities co-occur, barrier dysfunction is substantially amplified (OR exceeding 16 in paediatric cohorts). The combination is a strong candidate for a compound action.

The IL13 variant rs20541 (Arg130Gln) operates on the same allergic phenotype from the immune activation side, and the STAT3 variant rs17881320 influences downstream Th2 signalling. The 11q13.5 locus also physically co-localises with LRRC32/GARP, which independently affects regulatory T-cell function through TGF-β — a second mechanism at the same genomic address that compounds this locus's influence on allergic sensitisation.